Clinical application of inhibin A measurement: Prenatal serum screening for Down syndrome

Seminars in Reproductive Medicine

Volumn 22, Issue 3, 2004, Pages 235-242

  Lambert Messerlian, Geralyn M ^a,b   Canick, Jacob A ^b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Down syndrome; Inhibin A; Pregnancy; Screening

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRIOL; FOLLITROPIN; INHIBIN A;

CORPUS LUTEUM FUNCTION; COVARIANCE; DOWN SYNDROME; FEMALE; FERTILITY; FETOPLACENTAL UNIT; FETUS; FETUS DISEASE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LABORATORY DIAGNOSIS; NEGATIVE FEEDBACK; PREECLAMPSIA; PREMATURE LABOR; PRENATAL DIAGNOSIS; QUAD MARKER SCREENING; QUANTITATIVE DIAGNOSIS; REVIEW; SCREENING; SECOND TRIMESTER PREGNANCY; STATISTICAL SIGNIFICANCE;

DOWN SYNDROME; FEMALE; HUMANS; INHIBINS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 4344700745     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831899     Document Type: Review

References (73)

1. Ward OC. John Langdon Down: A Caring Pioneer. London, UK: The Royal Society of Medicine Press; 1998
2. Noble J. Natural history of Down's syndrome: a brief review for those involved in antenatal screening. J Med Screen 1998; 5:172-177
3. Wald N. Down's syndrome. In: Wald N, Leck I, eds. Antenatal and Neonatal Screening. Oxford: Oxford University Press; 2000:85-115
4. Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA 1983;249:2034-2038
5. Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement. A screening test for Down syndrome. Lancet 1984;1:926-929
6. Canick J, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated estriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988;95:330-333
7. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Br J Obstet Gynaecol 1988;95:334-341
8. Bogart M, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623-630
9. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ 1988;297:883-887
10. Wald NJ, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome. J Med Screen 1997;4:181-246
11. Groome N, O'Brien M. Immunoassays for inhibin and its subunits. J Immunol Methods 1993;165:167-176
12. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine, and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10:56-104
13. Groome NP, Illingworth PJ, O'Brien M, et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol (Oxf) 1994; 40:717-723
14. Lambert-Messerlian GM, Halle JE, Sluss PM, et al. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1994;79:45-50
15. Wallace EM, Crossley JA, Ritoe SC, Aitken DA, Spencer K, Groome NP. Evolution of an inhibin A ELISA method: implications for Down's syndrome screening. Ann Clin Biochem 1998;35:656-664
16. Knight GJ, Palomaki GE, Neveux LM, Haddow JE, Lambert-Messerlian GM. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down's syndrome screening. J Med Screen 2001;8:2-7
17. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143-153
18. Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels for twin pregnancies: implications for screening for Down's syndrome. Prenat Diagn 1996;16:927-929
19. Watt HC, Wald NJ, Smith D, et al. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. Prenat Diagn 1996;16:691-698
20. Wallace EM, Crossley JA, Ritoe SC, Groome NP, Aitken DA. Maternal serum inhibin-A in pregnancies complicated by insulin dependent diabetes mellitus. Br J Obstet Gynaecol 1997;104:946-948
21. Wald NJ, Watt HC, George L. Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. Prenat Diagn 1996;16:923-926
22. Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999;106:1304-1306
23. Maymon R, Shulman A. Integrated first- and second-trimester Down syndrome screening test among unaffected IVF pregnancies. Prenat Diagn 2004;24:125-129
24. Ferriman EL, Sehmi IK, Jones R, Cuckle HS. The effect of smoking in pregnancy on maternal serum inhibin A levels. Prenat Diagn 1999;19:372-374
25. Palomaki GE, Knight GJ, Haddow JE, Canick JA, Wald NJ, Kennard A. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol and hCG: impact on Down syndrome screening. Obstet Gynecol 1993;81:675-678
26. Maymon R, Sehmi IK, Herman A, Jones RG, Sherman D, Cuckle H. Serum inhibin A levels in pregnant women with systemic lupus erythematosus or antiphospholipid syndrome. Prenat Diagn 2000;20:12-16
27. Ferriman EL, Sehmi IK, Jones R, Railton A, Hilton RC, Cuckle HS. False-positive maternal serum screening in systemic lupus erythematosus: a case report. Prenat Diagn 2000;20:851-856
28. Bazzett LB, Yaron Y, O'Brien JE, et al. Fetal gender impact on multiple marker screening results. Am J Med Genet 1998; 76:369-371
29. Lam YH, Tang MH. The effect of fetal gender on second-trimester maternal serum inhibin-A concentration. Prenat Diagn 2001;21:662-664
30. Van Lith JMM, Pratt JJ, Beekhuis JR, Mantingh A. Second trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992;12:801-806
31. Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem 1993;30:219-220
32. Cuckle HS, Holding S, Jones R. Maternal serum inhibin levels in second trimester Down's syndrome pregnancies. Prenat Diagn 1994;14:387-390
33. Lambert-Messerlian GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, α inhibin precursor and activin in Down's syndrome pregnancy. J Med Screen 1996;3:58-62
34. Cuckle HS, Holding S, Jones R, Wallace EM, Groome NP. Maternal serum dimeric inhibin A in second-trimester Down's syndrome pregnancies. Prenat Diagn 1995;15:385-386
35. D'Antona D, Wallace EM, Shearing C, Ashby JP, Groome NP. Inhibin A and pro-αC inhibin in Down syndrome and normal pregnancies. Prenat Diagn 1998;18:1122-1126
36. Thirunavukarasu P, Lambert-Messerlian G, Robertson DM, Dawson G, Canick J, Wallace EM. Molecular weight forms of inhibin A, inhibin B and pro-C in maternal serum, amniotic fluid and placental extracts of normal and Down syndrome pregnancies. Prenat Diagn 2002;22:1086-1092
37. Debieve F, Beerlandt S, Hubinont C, Thomas K. Gonadotropins, prolactin, inhibin A, inhibin B, and activin A in human fetal serum from midpregnancy and term pregnancy. J Clin Endocrinol Metab 2000;85:270-274
38. Wallace EM, Crossley JA, Groome NP, Aitken DA. Amniotic fluid inhibin-A in chromosomally normal and Down's syndrome pregnancies. J Endocrinol 1997;152:109-112
39. Dalgliesh GL, Aitken DA, Lyall F, Howatson AG, Connor JM. Placental and maternal serum inhibin-A and activin-A levels in Down's syndrome pregnancies. Placenta 2001;22: 227-234
40. Lambert-Messerlian GM, Luisi S, Florio P, Mazza V, Canick JA, Petraglia F. Second trimester levels of maternal serum total activin A and placental inhibin/activin α and βA subunit messenger ribonucleic acids in Down syndrome pregnancy. Eur J Endocrinol 1998;138:425-429
41. Lambert-Messerlian GM, Canick JA, Palomaki GE. Maternal serum total activin A in pregnancies affected with fetal Down's syndrome [letter]. J Med Screen 1996;3:217
42. Cuckle HS, Sehmi I, Jones R, Evans LW. Maternal serum activin A and follistatin levels in pregnancies with Down syndrome. Prenat Diagn 1999;19:513-516
43. Wallace EM, Riley SC, Crossley JA, et al. Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy. J Clin Endocrinol Metab 1997;82:218-222
44. Lambert-Messerlian GM, Palomaki GE, Canick JA. Second trimester levels of maternal serum inhibin A in pregnancies affected by fetal neural tube defects. Prenat Diagn 2000;20: 680-682
45. Palomaki GE, Haddow JE, Knight GE, et al. Risk-based screening for trisomy 18 using alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Prenat Diagn 1995;15:713-723
46. Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin A as a marker for Down syndrome in early pregnancy. N Engl J Med 1996;334:1231-1236
47. Lambert-Messerlian GM, Saller DN Jr, Tumber MB, French CA, Peterson CJ, Canick JA. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn 1998;18: 1061-1067
48. Cuckle HS, Sehmi IK, Jones RG. Inhibin A and non-Down syndrome aneuploidy. Prenat Diagn 1999;19:787-792
49. Saller DN Jr, Canick JA, Blitzer MG, et al. Second-trimester maternal serum analyte levels associated with fetal trisomy 13. Prenat Diagn 1999;19:813-816
50. Hsu J, Chiang C, Hsieh C, Hsieh T. Elevated second-trimester maternal serum inhibin A levels in Asian pregnancies with fetal Down syndrome and other chromosomal abnormalities. Fetal Diagn Ther 2003;18:105-110
51. Watanabe H, Hamada H, Yamada N, et al. Second-trimester maternal pregnancy-associated plasma protein A and inhibin A levels in fetal trisomies. Fetal Diagn Ther 2002;17:137-141
52. Lambert-Messerlian GM, Saller DN, Tumber MB, et al. Second trimester maternal serum and inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn 1998;18:1061-1067
53. Saller DN Jr, Canick JA, Oyer CE. The detection of nonimmune hydrops through second-trimester maternal serum screening. Prenat Diagn 1996;16:431-435
54. Benn PA, Egan JF, Ingardia CJ. Extreme second-trimester serum analyte values in Down syndrome pregnancies with hydrops fetalis. J Matern Fetal Neonatal Med 2002;11:262-265
55. Oyer CE, Canick JA. Maternal serum hCG levels in triploidy: variability and need to consider molar tissue. Prenat Diagn 1992;12:627-629
56. Benn PA, Gainey A, Ingardia CJ, Rodis JF, Egan JFX. Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement. Prenat Diagn 2001;21:680-686
57. Connor JM, Ferguson-Smith MA. Essential Medical Genetics. 2nd ed. Oxford, UK: Blackwell Scientific; 1987:177
58. Aitken DA, Ireland M, Berry E, et al. Second-trimester pregnancy associated plasma protein A levels are reduced in Cornelia de Lange syndrome pregnancies. Prenat Diagn 1999;19:706-710
59. Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999;19:1035-1042
60. Haddow JE, Palomaki GE, Knight GJ, et al. Screening of maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998;338:955-961
61. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997;17:821-830
62. Malone FD, Wald NJ, Canick JA, et al. First- and second-trimester evaluation of risk (FASTER) trial: principal results of the NICHD multicenter Down syndrome screening study. Am J Obstet Gynecol 2003;189:S56
63. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10:56-104
64. Spencer K, Liao AW, Ong CYT, Geerts L, Nicolaides KH. Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester. Prenat Diagn 2001;21:441-444
65. Noble PL, Wallace EM, Snijders RJM, Groome NP, Nicolaides KH. Maternal serum inhibin-A and free β-hCG concentrations in trisomy 21 pregnancies at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1997;104:367-371
66. Wallace EM, Grant VE, Swanston IA, Groome NP. Evaluation of maternal serum dimeric inhibin A as a first-trimester marker of Down's syndrome. Prenat Diagn 1995;15: 359-362
67. Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996;103:407-412
68. Lambert-Messerlian GM, Palomaki GE, Knight GJ, Neveux LM, Canick JA, Haddow JE. Dimeric inhibin-A as a marker for Down syndrome in the first trimester. Annual Meeting of the American College of Medical Genetics; March 4-7, 2004; Orlando, FL
69. Stranc LC, Evans JA, Hamerton JL. Chorionic villus sampling and amniocentesis for prenatal diagnosis. Lancet 1997;349:711-714
70. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 1999;341:461-467
71. Muttukrishna S, George L, Fowler PA, Groome NP, Knight PG. Measurement of serum concentration of inhibin-A (α-βA dimer) during human pregnancy. Clin Endocrinol (Oxf) 1995;42:391-397
72. Reis FM, D'Antona D, Petraglia F. Predictive value of hormone measurements in maternal and fetal complications of pregnancy. Endocr Rev 2002;23:230-257
73. Lambert-Messerlian G. Physiology and pathophysiology of inhibin A and activin A in human pregnancy. Curr Opin Endocrinol Diabetes 2000;7:337-344